Services activity is picking up again, with the latest US composite PMI showing the strongest expansion since April 2022 and services leading the charge. That kind of broad demand often rewards companies that can grow earnings without relying on cheap money or booming credit. This is where the Healthy high growth potential screener comes in. This article highlights three stocks from the screener that fit that profile.

The stocks highlighted below are only a small sample of what qualifies, with the full screen surfacing 282 more companies that also combine solid financial profiles with healthy growth potential that this article does not cover. To identify candidates that fit your own style, head straight into the Healthy high growth potential screener to filter, analyze, and focus on the highest conviction ideas for you.

Amylyx Pharmaceuticals (AMLX)

Overview: Amylyx Pharmaceuticals is a Cambridge based clinical stage company developing treatments for neurodegenerative and rare endocrine conditions, with AMX0114 for ALS and AMX0035 for Wolfram syndrome as key pipeline assets that link directly to the Healthy high growth potential theme. Alongside these neuro programs, Amylyx is building a GLP 1 receptor antagonist franchise, including avexitide for post bariatric hypoglycemia, which is intended to turn its R&D pipeline into future earnings rather than relying on current product sales.

Market Cap: US$4.3b

Amylyx Pharmaceuticals may appeal to investors who want exposure to a high growth pipeline where earnings potential is tied to a few high impact clinical assets rather than a mature product portfolio. LUCIDITY Phase 3 data for avexitide point to a possible first commercial product in post bariatric hypoglycemia from 2027. AMX0114 and AMX0035 extend that opportunity into neurodegenerative diseases, which is why analysts see strong earnings and revenue growth ahead. The trade off is clear: Amylyx is still loss making, relies on external funding, and any setback in clinical data, regulation or payer coverage could affect both valuation and dilution risk. For investors who are comfortable with clinical and funding risk, the combination of a clean balance sheet, cash runway into 2028 and multiple shots on goal in high unmet need diseases presents a high growth story that is still unfolding.

Accelerating trial milestones are only part of Amylyx Pharmaceuticals' story. The real swing factor is what analysts expect those programs to mean for future earnings. Get the analyst forecasts for Amylyx Pharmaceuticals to see what the market might be missing.

Iovance Biotherapeutics (IOVA)

Overview: Iovance Biotherapeutics is a commercial stage biotech company focused on autologous tumor infiltrating lymphocyte therapies, led by Amtagvi for advanced melanoma and a late stage lifileucel and LN 145 pipeline for other hard to treat solid tumors such as NSCLC, cervical, endometrial and head and neck cancers that aligns closely with the Healthy high growth potential theme.

Operations: Iovance Biotherapeutics generated about US$325 million in revenue from its TIL based therapies and related activities, with roughly US$321 million coming from the United States and the remainder from other markets.

Market Cap: US$3.8b

Iovance Biotherapeutics is attracting attention because Amtagvi is already on the market and revenue is growing from that base. Analysts expect earnings to rise quickly as more centers adopt TIL therapy and margins improve. At the same time, the broader lifileucel and LN 145 pipeline in additional solid tumors gives the company several shots at expanding its addressable market beyond melanoma. Recent analyst price target increases and international approvals highlight confidence in that path. Investors still need to weigh current losses, funding and dilution risk and the company’s reliance on oncology cell therapy rather than a broad product mix, which is why a closer look at how its growth, balance sheet and pipeline fit together can be so important.

Revenue at Iovance Biotherapeutics is already real and the TIL pipeline could reshape its future, yet the full risk and reward picture is easy to miss at a glance. Read the 2 key rewards and 2 important warning signs (1 is major!)

Space Exploration Technologies (SPCX)

Overview: Space Exploration Technologies runs a three part business that includes reusable rockets, the Starlink satellite broadband network and an AI platform built around Grok and related services. For the Healthy high growth potential theme, the key link is Starlink, which sells satellite based internet to consumers, enterprises and governments worldwide, while launch and AI activities still contribute a large share of overall revenue.

Operations: Space Exploration Technologies generates about US$13.9b from Connectivity, US$5.1b from AI and US$4.1b from its Space segment.

Market Cap: US$1,859.1b

Space Exploration Technologies attracts interest because Starlink’s satellite broadband engine sits alongside a growing AI platform and a long history in launch services. Together, these segments support an earnings growth profile that fits this screener. Analysts describe expectations for expansion in revenue and earnings over the next 3 years, helped by subscriber growth, AI contracts and government work, even though the company is still reporting losses and has less than a year of cash runway. That mix of expected growth, tight funding and a rich valuation means outcomes could be wide. For investors willing to accept that trade off, the combination of Starlink scale, AI ambitions and an experienced, long tenured leadership team may be compelling.

Space Exploration Technologies is trying to fuse rockets, Starlink and AI into one growth story, yet the full earnings trade off is not obvious at first glance. See how the analyst forecasts for Space Exploration Technologies could shift the risk profile in ways the headline numbers do not fully reveal.

Seeking Fresh Alternatives Before Others Do

Markets can move quickly and some of the most interesting stocks may gain momentum before most investors notice. Review these fresh ideas while they are still relatively under the radar.

• Spot potential breakout miners before gold sentiment changes by checking the curated 32 elite gold producer stocks that screens for producers with meaningful scale and staying power.
• Review structural shifts in global infrastructure by using the focused 39 power grid technology and infrastructure stocks built around companies tied to grid upgrades, reliability, and long term demand trends.
• Explore shifting industrial demand with the hand picked 9 top copper producer stocks that filters producers positioned for long haul electrification themes.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.